Want to see TSE:INNO full AI Analyst Report?
INNO Stock Chart & Stats
C$2.70
C$0.25(9.26%)
At close: 4:00 PM EDT
C$2.70
C$0.25(9.26%)
Day’s Range― - ―
52-Week RangeC$2.15 - C$21.00
Previous CloseN/A
Volume100.00
Average Volume (3M)920.00
Market Cap
C$10.35M
Enterprise ValueC$4.95M
Total Cash (Recent Filing)C$6.68M
Total Debt (Recent Filing)C$1.42M
Price to Earnings (P/E)―
Beta-0.72
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding4,498,772
10 Day Avg. Volume392
30 Day Avg. Volume920
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Cannabinoid Delivery TechnologyA focused business model built around cannabinoid formulations and proprietary long-acting/controlled-release delivery gives durable differentiation. This supports longer-term licensing, clinical development pathways and niche market positioning that can generate recurring product revenues and partnership deals once clinical validation is achieved.
Very High Gross MarginsGross margins near 90% indicate product economics and manufacturing or IP-based pricing power that are structurally attractive. If operating expenses stabilize, those margins enable rapid operating leverage and scalable profitability as revenue growth resumes or commercial partnerships expand.
Relatively Solid Balance Sheet LeverageModerate leverage (debt-to-equity ~0.27) and meaningful equity and asset base provide runway to fund near-term development without immediate insolvency risk. This structural financial buffer reduces short-term default risk and supports pursuing partnerships or R&D before profitability is achieved.
Bears Say
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow signal structural cash burn rather than a timing gap. Over a 2-6 month horizon this increases the likelihood management must raise capital, cut investment, or dilute shareholders, constraining strategic flexibility and product development cadence.
Revenue DecelerationAfter prior multi-year expansion, a TTM revenue decline indicates the growth engine is stalling. Slower topline undermines scale benefits tied to high gross margins and lengthens the timeline to break-even, increasing execution risk and pressure on cash and stakeholder patience.
Ongoing Losses And Negative ReturnsPersistent net losses and negative ROE show capital is not yet producing returns. This structural profitability gap forces reliance on external funding or dilution, limits reinvestment capacity, and raises the bar for management to convert strong unit economics into sustained corporate profitability.
InnoCan Pharma News
INNO FAQ
What was InnoCan Pharma’s price range in the past 12 months?
InnoCan Pharma lowest stock price was C$2.15 and its highest was C$21.00 in the past 12 months.
What is InnoCan Pharma’s market cap?
InnoCan Pharma’s market cap is C$10.35M.
When is InnoCan Pharma’s upcoming earnings report date?
InnoCan Pharma’s upcoming earnings report date is Aug 31, 2026 which is in 17 days.
How were InnoCan Pharma’s earnings last quarter?
InnoCan Pharma released its earnings results on May 27, 2026. The company reported -C$0.296 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.296.
Is InnoCan Pharma overvalued?
According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued.
Does InnoCan Pharma pay dividends?
InnoCan Pharma does not currently pay dividends.
What is InnoCan Pharma’s EPS estimate?
InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCan Pharma have?
InnoCan Pharma has 4,498,772 shares outstanding.
What happened to InnoCan Pharma’s price movement after its last earnings report?
InnoCan Pharma reported an EPS of -C$0.296 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.88%.
Which hedge fund is a major shareholder of InnoCan Pharma?
Currently, no hedge funds are holding shares in TSE:INNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InnoCan Pharma
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland, France, and various international markets. The company actively pursues research and development into treatments for conditions such as COVID-19, leveraging CBD delivered via exosomes and liposomes. InnoCan's product line features a range of CBD-infused topical items, including eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Beyond R&D, the corporation is also involved in the marketing and distribution of its proprietary CBD-enhanced pharmaceutical and cosmetic offerings. Established in 2018, InnoCan Pharma Corporation maintains its principal office in Calgary, Canada.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Voyageur Pharmaceuticals
―
Avicanna
―